Celldex Therapeutics IncChange company Symbol lookupSelect an option...CLDX Celldex Therapeutics IncWRLD World Acceptance CorpCWD CaliberCos IncLNTH Lantheus Holdings IncDFIN Donnelley Financial Solutions IncSY So-Young International IncGOTU Gaotu Techedu IncSGDVV Safe & Green Development CorpGLBZ Glen Burnie BancorpPHAR Pharming Group NVGo
Celldex Therapeutics, Inc. is a biopharmaceutical company. It is focused on developing therapeutic monoclonal and bispecific antibodies that address diseases for which available treatments are inadequate. Its drug candidates include antibody-based therapeutics, which has the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. Its bispecific platform includes CDX-585 and CDX-527. CDX-585 combines its active PD-1 blockade and anti-ILT4 blockade to prevent immunosuppressive signals in T cells and myeloid cells, respectively. Its other programs include CDX-1140, a fully human agonist monoclonal antibody targeted to CD40.
|
|
|
|
| |
CLDX's position in the Biotechnology industry
| Industry Peers | EBS | CMRX | |
|---|---|---|---|
Summary | |||
| Company Profile | Celldex Therapeutics, Inc. is a biopharmaceutical company. It is focused on developing therapeutic monoclonal and bispecific antibodies that address diseases for which available treatments are... | Emergent BioSolutions, Inc. is a life sciences company providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats (PHTs). Its... Go to EBS summary | Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201... Go to CMRX summary |
| 52-Week Change | VS. INDUSTRY | -83.90% | -47.49% |
| Market Cap | VS. INDUSTRY | $178.2M | $92.6M |
| Beta | VS. INDUSTRY | 0.9 | 1.1 |
| Dividend Yield | VS. INDUSTRY | -- | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | -- | 0.51x |
| Data as of | |||
Fundamentals | |||
| Total Revenue (TTM) | VS. INDUSTRY | $1.1B | $33.7M |
| Profit Margin | VS. INDUSTRY | -56.63% | 535.82% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | -- | -- |
| Revenue Growth (TTM) | VS. INDUSTRY | -32.99% | 5,439.15% |
| Data as of |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.